- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12.25 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 12 | Seeking Alpha | ||
| 05.12.25 | Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule | 1 | Investing.com | ||
| 04.12.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.11.25 | Intensity Therapeutics GAAP EPS of -$0.06 in-line | 8 | Seeking Alpha | ||
| 06.11.25 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 115 | PR Newswire | The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate... ► Artikel lesen | |
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.10.25 | Intensity Therapeutics announces pricing of $4M registered direct offering of common stock | 11 | Seeking Alpha | ||
| 31.10.25 | Kapitalerhöhung mit hohem Abschlag: Aktie von Intensity Therapeutics stürzt ab | 16 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics stock tumbles after pricing $4 million offering | 3 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics sichert sich 4 Millionen US-Dollar durch registrierte Direktplatzierung | 11 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics prices $4 million registered direct offering | 1 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know | 14 | Benzinga.com | ||
| 30.10.25 | Intensity Therapeutics stock soars after phase 1/2 data publication | 10 | Investing.com | ||
| 30.10.25 | Intensity Therapeutics publishes cancer treatment study results in Lancet journal | 27 | Investing.com | ||
| 23.10.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 11 | SEC Filings | ||
| 10.09.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09.25 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update | 412 | PR Newswire | A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed... ► Artikel lesen | |
| 20.08.25 | Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution | 10 | Investing.com | ||
| 12.08.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,60 | +0,88 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| NOVAVAX | 6,299 | -0,08 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,800 | -3,70 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| EDITAS MEDICINE | 1,819 | -1,20 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,200 | +5,13 % | Führungswechsel bei Ginkgo Bioworks: COO Reshma Shetty übergibt operative Verantwortung | ||
| IOVANCE BIOTHERAPEUTICS | 2,116 | -5,37 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
| NOVOCURE | 12,780 | +0,08 % | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,034 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| MACROGENICS | 1,620 | +5,13 % | MacroGenics, Inc.: MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress | Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealigned... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,225 | +0,91 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals: Milliardenversprechen Mavorixafor | Die Aktie von X4 Pharmaceuticals gewinnt an Bedeutung, da das Unternehmen seinen einzigen Wirkstoff Mavorixafor Schritt für Schritt in neue Märkte bringt und klinisch weiterentwickelt. Mit wichtigen... ► Artikel lesen | |
| GENERATION BIO | 5,500 | +0,55 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 2,220 | -4,72 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones | Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,416 Euro und damit -4,39 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.